- Category: Experimental HCV Drugs
- Published on Friday, 25 April 2014 00:00
- Written by AbbVie
AbbVie announced this week that it has submitted a New Drug Application to the U.S. Food and Drug Administration seeking approval of its "3D" regimen of direct-acting antivirals -- ABT-450/ritonavir, ombitasvir (ABT-267), and dasabuvir (ABT-333), to be used with or without ribavirin. 3D has been designated as an FDA "breakthrough therapy" and an approval decision is expected by the end of the year.
As reported at the recent EASL International Liver Congress, the AbbVie combination has demonstrated excellent sustained response rates, including for treatment-experienced hepatitis C patients, people with liver cirrhosis, and liver transplant recipients.
Below is an edited excerpt from an AbbVie press release describing the NDA submission.
AbbVie Submits New Drug Application to the U.S. FDA for its Investigational, All-oral, Interferon-free Therapy for the Treatment of Hepatitis
Submission based on the largest Phase III program in genotype 1 (GT1) hepatitis C patients conducted to date
AbbVie's investigational regimen was designated as a breakthrough therapy by the FDA
AbbVie plans to submit applications for regulatory approval of its regimen in the European Union in early May
North Chicago, Ill. -- April 22, 2014-- AbbVie (NYSE: ABBV) submitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the company's investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection. The NDA is supported by data from the largest all-oral, interferon-free clinical program in GT1 patients conducted to date, with six Phase III studies that included more than 2,300 patients in over 25 countries.
"This NDA submission is a significant advancement for AbbVie's HCV development program," said Scott Brun, MD, vice president, Pharmaceutical Development, AbbVie. "Based on the robust data that have been generated in our international Phase III HCV program, we believe our all-oral, interferon-free regimen holds the potential to be a promising new therapy for patients living with this chronic infection."
In May of 2013, AbbVie's investigational direct-acting antiviral (DAA) regimen with and without ribavirin for HCV genotype 1 was designated as a Breakthrough Therapy by the U.S. FDA. This designation is intended to help expedite the development of drugs for serious or life-threatening conditions and is based in part on preliminary clinical evidence demonstrating a drug or regimen may have substantial improvement on at least one clinically significant endpoint compared to available therapy.
AbbVie plans to submit applications for regulatory approval of its regimen in the European Union in early May.
In the U.S., an estimated 3.2 million people are living with HCV and the infection is most prevalent among those born between 1945 and 1965.
About AbbVie's Investigational HCV Regimen
The AbbVie investigational regimen consists of the fixed-dose combination of ABT-450/ritonavir (150/100 mg) co-formulated with ombitasvir (ABT-267) 25 mg, dosed once daily, and dasabuvir (ABT-333) 250 mg with or without ribavirin (weight-based), dosed twice daily. The combination of three different mechanisms of action interrupts the hepatitis C virus replication process with the goal of optimizing sustained virologic response rates across different patient populations.
Additional information about AbbVie's Phase III studies can be foundon www.clinicaltrials.gov.
AbbVie's HCV Development Program
The AbbVie HCV clinical development program is intended to advance scientific knowledge and clinical care by investigating an interferon-free, all-oral regimen with and without ribavirin with the goal of producing high sustained virologic response rates in as many patients as possible, including those that typically do not respond well to treatment, such as previous non-responders to interferon-based therapy or patients with advanced liver fibrosis or cirrhosis.
ABT-450 was discovered during the ongoing collaboration between AbbVie and Enanta Pharmaceuticals (NASDAQ: ENTA) for hepatitis C virus protease inhibitors and regimens that include protease inhibitors. ABT-450 is being developed by AbbVie for use in combination with AbbVie's other investigational medicines for the treatment of hepatitis C.
AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. AbbVie employs approximately 25,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, pleasevisitwww.abbvie.com. Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.
AbbVie. AbbVie Submits New Drug Application to the U.S. FDA for its Investigational, All-oral, Interferon-free Therapy for the Treatment of Hepatitis C. Press release. April 22, 2014.